Literature DB >> 20211326

Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation.

Cedric Delhaye1, Gabriel Maluenda, Kohei Wakabayashi, Itsik Ben-Dor, Gilles Lemesle, Sara D Collins, Asmir I Syed, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, William O Suddath, Lowell F Satler, Kenneth M Kent, Joseph Lindsay, Augusto D Pichard, Ron Waksman.   

Abstract

C-reactive protein (CRP) elevation is associated with an adverse cardiovascular prognosis after bare metal stent implantation. Data have suggested a similar association between preprocedural CRP and adverse events after drug-eluting stent (DES) implantation. The present study was designed to address whether such a relation exists after DES placement. After excluding patients presenting with an acute coronary syndrome with troponin I elevation, we analyzed the data from 936 consecutive patients who had undergone DES implantation from 2003 to 2007 and had a preprocedural CRP measurement. The patients were divided into 3 groups according to the preprocedural CRP level (<1.31, 1.31-3.76, and >3.76 mg/L). The primary end point was the composite of death and Q-wave myocardial infarction (QWMI) at 2 years of follow-up. Target vessel revascularization was also assessed. The rate of death/QWMI was not significantly different statistically among the CRP tertiles during the in-hospital period (0.6% vs 0.0% vs 0.6%, p = 0.5) or at 1 year of follow-up (1.9% vs 2.9% vs 4.5%, p = 0.2). At 2 years, death/QWMI had occurred in 2.9% of patients in the lowest, 5.2% in the middle, and 8.8% in the highest tertile (p = 0.006). The incidence of target vessel revascularization was similar in the 3 groups at 2 years of follow-up (13.2% vs 14.9% vs 16.9%, p = 0.5). On multivariate analysis, the upper tertile of CRP was an independent predictor of death/QWMI at 2 years (hazard ratio 2.5, 95% confidence interval 1.1 to 5.4, tertile 3 vs tertile 1, p = 0.006). In conclusion, high preprocedural CRP levels are associated with an increased risk of death and QWMI after DES implantation at long-term follow-up but not acutely. The CRP levels were not related to target vessel revascularization. Thus, an elevated CRP level in this population appears to be more of a marker of global cardiovascular risk than a predictor of post-DES-related complications. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20211326     DOI: 10.1016/j.amjcard.2009.10.064

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Role of pre-procedural C-reactive protein level in the prediction of major adverse cardiac events in patients undergoing percutaneous coronary intervention: a meta-analysisof longitudinal studies.

Authors:  Singh-Baniya Bibek; Yong Xie; Jia-Jia Gao; Zhi Wang; Jing-Feng Wang; Deng-Feng Geng
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

2.  Synthetic peptide fragment (65-76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting.

Authors:  T I Arefieva; T L Krasnikova; A V Potekhina; N U Ruleva; P I Nikitin; T I Ksenevich; B G Gorshkov; M V Sidorova; Zh D Bespalova; N B Kukhtina; S I Provatorov; E A Noeva; E I Chazov
Journal:  Inflamm Res       Date:  2011-07-10       Impact factor: 4.575

3.  High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention: a meta-analysis of twenty-four randomized controlled trials.

Authors:  Le Wang; Pingan Peng; Ou Zhang; Xiaohan Xu; Shiwei Yang; Yingxin Zhao; Yujie Zhou
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

4.  Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis.

Authors:  Shi-Jie Zhao; Zhao-Shuang Zhong; Guo-Xian Qi; Li-Ye Shi; Ling Chen; Wen Tian
Journal:  PLoS One       Date:  2016-05-10       Impact factor: 3.240

5.  Statin in the treatment of patients with myocardial infarction: A meta-analysis.

Authors:  Xue Han; Yi Zhang; Lin Yin; Lin Zhang; Yue Wang; Hongshan Zhang; Bo Li
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

6.  Associations among circulating levels of follistatin-like 1, clinical parameters, and cardiovascular events in patients undergoing elective percutaneous coronary intervention with drug-eluting stents.

Authors:  Tatsuro Aikawa; Kazunori Shimada; Katsumi Miyauchi; Tetsuro Miyazaki; Eiryu Sai; Shohei Ouchi; Tomoyasu Kadoguchi; Mitsuhiro Kunimoto; Yusuke Joki; Tomotaka Dohi; Shinya Okazaki; Kikuo Isoda; Koji Ohashi; Toyoaki Murohara; Noriyuki Ouchi; Hiroyuki Daida
Journal:  PLoS One       Date:  2019-04-29       Impact factor: 3.240

7.  Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation.

Authors:  Hye Won Lee; Han Cheol Lee; Bo Won Kim; Mi Jin Yang; Jin Sup Park; Jun Hyok Oh; Jung Hyun Choi; Kwang Soo Cha; Taek Jong Hong; Sang-Pil Kim; Seunghwan Song; Jong-Ha Park
Journal:  Yonsei Med J       Date:  2013-11       Impact factor: 2.759

8.  Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention.

Authors:  Norihito Takahashi; Tomotaka Dohi; Hirohisa Endo; Takehiro Funamizu; Hideki Wada; Shinichiro Doi; Yoshiteru Kato; Manabu Ogita; Iwao Okai; Hiroshi Iwata; Shinya Okazaki; Kikuo Isoda; Katsumi Miyauchi; Kazunori Shimada
Journal:  J Clin Med       Date:  2020-04-06       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.